Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477835 | PMC |
| http://dx.doi.org/10.4103/ajns.AJNS_100_21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Addressing the role of surgery in brain tumour trials: A report from the neurosurgery committee of the EORTC brain tumour group.
Eur J Cancer
December 2024
Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
The Brain Tumor Group (BTG) of the European Organization for Research and Treatment of Cancer (EORTC) conducts academic clinical trials and translational research to improve clinical management of patients with primary and secondary brain tumors. The EORTC BTG has traditionally played an important role in providing evidence and thus advancing the field, albeit with a main focus on radiotherapy and pharmacotherapy in gliomas. Although examples of well-designed neuro-oncological surgical trials can be found, evidence in surgical neuro-oncology predominantly includes data from uncontrolled prospective series or retrospective cohorts.
View Article and Find Full Text PDFNeuro-Oncological Superiority of Supratotal Resection in Lower-Grade Gliomas.
Neuro Oncol
December 2024
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano.
Background: Supratotal-Resection (SpTR) is a promising surgical strategy in Lower-grade gliomas (LGGs). SpTR assessment, feasibility and distinctive features, as well as clinical benefit at first and second surgery and on overall-survival must be better characterized. The critical percentage of resection exceeding FLAIR margins to obtain clinical benefit and its impact on long-term functional performance are also undefined.
View Article and Find Full Text PDFInfluence of neuropathological diagnosis on psychooncological distress in neurooncological patients - a retrospective cross-sectional analysis.
Front Oncol
November 2024
Department of Neurosurgery, University Hospital Duesseldorf, Duesseldorf, Germany.
Background: Gliomas, the most common primary brain tumours, are classified based on histology and molecular genetics. Glioblastomas (GBM) are highly aggressive and are graded as WHO grade 4, while astrocytoma and oligodendrogliomas fall under WHO grades 2-3 (4). Gliomas affect 6 per 100,000 people, with a higher incidence in men.
View Article and Find Full Text PDFInterventional neurorehabilitation for glioma patients: A systematic review.
Neurooncol Pract
December 2024
Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Unlabelled: Harnessing the neuroplastic potential of the human brain is being increasingly recognized as an important neuro-oncological paradigm to facilitate safe resection of brain tumors while preserving neurological function and quality of life. Interventional neurorehabilitation, employing both invasive and noninvasive neuromodulation techniques, represents an important emerging therapeutic strategy to induce or enhance neural plasticity to promote functional recovery in brain tumor patients. This study aimed to conduct a comprehensive review of interventional neurorehabilitation techniques for glioma patients.
View Article and Find Full Text PDFPartial Sacrectomy With Lumbopelvic Fixation for Sacral Giant Cell Tumor: Emphasizing Optimal Neuro-Oncological Outcomes.
Cureus
October 2024
Neurosurgery, Dr. D. Y. Patil Medical College, Hospital & Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to be University), Pune, IND.
Giant cell tumors (GCTs) of bone are classified as intermediate malignant tumors with a significant potential for local infiltration. Despite their benign histopathological appearance, these tumors exhibit extreme local aggression. The sacrum is the most commonly affected spinal region, followed by the lumbar, cervical, and thoracic regions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!